Home Contact Details   Research Teaching Software Links Projects


Research

My main research interest concerns the analysis of gene expression data obtained from breast cancer samples. The aim is to identify the key genes related to the evolution of cancer or the effect of a treatment. The resulting biological knowledge should allow us to bring new insights into breast cancer biology and to build new prognostic and predictive tools to improve the management of patients.

The gene expression profiling generates a huge amount of data 
and the Machine Learning methods are good candidates to analyze such data. The use of survival analysis coupling to Machine Learning methods (e.g. feature selection, cross-validation, etc) need to be studied carefully in order to adapt the methodology to such problems.

The new methods are tested on original data coming from the Functional Genomics and Translational Research Unit at the Institut Jules Bordet and numerous international collaborations.


Research Interests
  • Gene expression Profiling
  • Survival Analysis
  • Classification and Regression
  • Meta-Analysis
  • Clustering


Research Groups


Publications

A list of my publications is also available on my Harvard webpage.

Book Chapter



Editorial

  • Time to move forward from "first generation" prognostic gene signatures in early breast cancer. Desmedt C, Michiels S, Haibe-Kains B, Loi S, Sotiriou C, Editorial in Breast Cancer Research and Treatment, in press, 2010.

  • Classification models for breast cancer molecular subtyping: What is the best candidate for a translation into clinic? Haibe-Kains B, Editorial in Women’s Health, in press, September 2010.

International Journal

  • Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS). Toussaint J, Durbecq V, Altintas S, Doriath V, Rouas G, Paesmans M, Bedard P, Haibe-Kains B, Tjalma WA, Larsimont D, Piccart MJ, Sotiriou C in PLoS ONE, 5(8):e12100, 2010. [PDF]
  • Long term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Le Calvé B, Rynkowski M, LeMercier M, Bruyère C, Lonez C, Gras T, Haibe-Kains B, Bontempi G, Decaestecker C, Ruysschaert JM, Kiss R and Lefranc F in Neoplasia, 12(9):727-739, 2010. [PDF]
  • PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor positive breast cancer. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans FW, Bardelli A, Ellis P, Tutt AN, Gillett CE, Mills GB, Hennessy BT , Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C in PNAS, in press, 2010. [PDF] [BibTeX]
  • Evaluation of an RNA interference screen-derived mitotic and ceramide pathway meta- gene in paclitaxel-treated primary ER-/PR-/ERBB2- breast cancer: a retrospective analysis of five clinical trials. Juul N, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans FW, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Szallasi Z and Swanton C in Lancet Oncology, in press, 2010. [PDF] [BibTeX]
  • A fuzzy gene expression-based computational approach improves breast cancer prognostication. Haibe-Kains B*, Desmedt C*, Rothé F, Sotiriou C and Bontempi G in Genome Biology, volume 11, number 2, pages R18, 2010. [PDF] [BibTeX]
  • Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, Richardson AL, Wang ZC in Nature Medecine, volume 16, number 2, pages 214-218, 2010. [PDF] [BibTeX]
  • Long-term Temozolomide Treatment Induces Marked Amino Metabolism Modifications and an Increase in TMZ Sensitivity in Hs683 Oligodendroglioma Cells. Lamoral-Theys D, Le Mercier M, le Calve B, Rynkowski MA, Bruyere C, Deacestecker C, Haibe-Kains B, Bontempi G, Dubois J, Lefranc F and Kiss R in Neoplasia, volume 12, number 1, 2010. PDF] [BibTeX]
  • Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. Toussaint J, Sieuwerts AM, Haibe-Kains B, Desmedt C, Rouas G, Harris AL, Larsimont D, Piccart MJ, Foekens JA, Durbecq V and Sotiriou C in BMC Genomics, volume 10, number 424, September 2009. [Abstract] [PDF] [BibTeX]
  • The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. Desmedt C, Giobbie-Hurder 1, Neven P, Paridaens R, Christiaens M, Smeets A,  Lallemand F, Haibe-Kains B, Viale G, Gelber RD, Piccart MJ, Sotiriou C  in BMC Medical Genomics, volume 2, number 40, July 2009. [Abstract] [PDF] [BibTeX]
  • Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. Loi S, Sotiriou C, Haibe-Kains B, Lallemand F, Conus NM, Piccart MJ, Speed TP, McArthur GA in BMC Medical Genomics, volume 2, number 37, July 2009. [Abstract] [PDF] [BibTeX]
  • Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways. Ravoet M, Sibille C, Gu C, Libin M, Haibe-Kains B, Sotiriou C, Goldman M, Roufosse F and Willard-Gallo K in Blood, June 2009. [Abstract] [PDF] [BibTeX]
  • The Genomic Grade Index (GGI) Is Associated with Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer. Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer H, Hortobagyi, Piccart MJ, Sotiriou C and Pusztai L in Journal of Clinical Oncology, volume 27, number 19, pages 3185-3191, July 2009. [Abstract] [PDF] [BibTeX]
  • Galectin-1 Proangiogenic and Pro-Migratory Effects in the Hs683 Oligodendroglioma Model Are Partly Mediated Through  the Control of BEX2 Expression. Le Mercier M, Fortin S, Mathieu V, Roland I, Spiegl-Kreinecker S, Haibe-Kains B, Bontempi G, Decaestecker C, Berger W, Lefranc F and Kiss R in Neoplasia, volume 11, number 5, pages 485-496, May 2009. [Abstract] [PDF] [BibTeX]
  • Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA. Stamatopoulos B, Haibe-Kains B, Equeter C, Meuleman N, Sorée A, De Bruyn C, Hanosset D, Bron D, Martiat P and Lagneaux L in HaematologicaApril 2009. [Abstract] [PDF] [BibTeX]
  • MicroRNA-29c and microRNA-223 downregulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van Den Neste E, Michaux L, Heimann P, Martiat P, Bron D and Lagneaux L in Blood, volume 113, number 21, pages 5237-5245, May 2009. [Abstract] [PDF] [BibTeX]
  • Comparison of Prognostic Gene Expression signatures for Breast Cancer. Haibe-Kains B*, Desmedt C*, Piette F, Buyse M, Cardoso F, van‘t Veer L, Piccart MJ, Bontempi G and Sotiriou C  in BMC Genomics, volume 9, number 394, August 2008. [Abstract] [PDF] [BibTeX]
  • A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Haibe-Kains B,  Desmedt C, Sotiriou C and Bontempi G in Bioinformatics, volume 24, number 19, pages 2200-2208, July 2008. [Abstract] [PDF] [BibTeX]
  • Meta-analysis of Gene-Expression Profiles in Breast Cancer: Toward a Unified Understanding of Breast Cancer Sub-typing and Prognosis Signatures. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, Piccart MJ and Delorenzi M  in Breast Cancer Research, volume 10, number 4, R65, August 2008. [Abstract] [PDF] [BibTeX]
  • Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Desmedt C*, Haibe-Kains B*, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, and Sotiriou C in Clinical Cancer Research, volume 14, number 16, pages 5158-5165, August 2008. [Abstract] [PDF] [BibTeX]
  • Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. Loi S*, Haibe-Kains B*, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EMJJ, Jansen MPHM, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ and Sotiriou C in BMC Genomics, volume 9, number 239, May 2008. [Abstract] [PDF] [BibTeX]
  • Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity. Mijatovic T, De Neve N, Gailly P,  Mathieu V, Haibe-Kains B, Bontempi G, Lapeira J, Decaestecker C, Facchini V and Kiss R in Molecular Cancer Therapeutics, volume 7, number 5, pages 1285-1296, May 2008. [Abstract] [PDF] [BibTeX]
  • UNBS5162, a Novel Naphthalimide That Decreases CXCL Chemokine Expression in Experimental Prostate Cancers. Mijatovic T, Mahieu T, Bruyère C, De Nève N, Dewelle J, Simon G, Dehoux MJM, van der Aar E, Haibe-Kains B, Bontempi G, Decaestecker C, Van Quaquebeke E, Darro F and Kiss R in Neoplasia, volume 10, number 6, pages 573-586, May 2008. [Abstract] [PDF] [BibTeX]
  • Evidence of galectin-1 involvement in glioma chemoresistance. Le Mercier M, Lefranc F, Mijatovic T, Debeir O, Haibe-Kains B, Bontempi G, Decaestecker C, Kiss R and Mathieu V  in Toxicology and Applied Pharmacology, volume 229, number 2, pages 172-183, January 2008. [Abstract] [PDF] [BibTeX]
  • Quantification of ZAP70 mRNA in B Cells by Real-Time PCR Is a Powerful Prognostic Factor in Chronic Lymphocytic Leukemia. Stamatopoulos B, Meulemans N, Haibe- Kains B, Duvillier H, Massy M, Martiat P, Bron D, and Lagneaux L in Clinical Chemistry, volume 53, number 10, August 2007. [Abstract] [PDF] [BibTeX]
  • 4-IBP: A s1 Receptor Agonist Decreases the Migration of Human Cancer Cells Including Glioblastoma Cells In Vitro and Sensitizes Them In Vitro and In Vivo to the Cytotoxic Insults of Pro-Apoptotic and Pro-Autophagic Drugs. Mégalizzi V, Mathieu V, Mijatovic T, Gailly P, Debeir O, De Neve N, Van Damme M, Bontempi G, Haibe-Kains B, Decaestecker C, Kondo Y, Kiss R and Lefranc F in Neoplasia, volume 9, number 5, May 2007. [Abstract] [PDF] [BibTeX]
  • Strong time-dependency of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multi-centre independent validation series. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, Saghatchian d’Assignies M, Bergh J, Lidereau R, Ellis P, Harris A, Klijn JG, Foekens JA, Cardoso F, Piccart M, Buyse M and Sotiriou C in Clinical Cancer Research, volume 13, number 11, pages 3201-3214, June 2007. [Abstract] [PDF] [BibTeX]
  • Definition of clinically distinct molecular subtypes in estrogen receptor positive breast carcinomas through use of genomic grade. Loi S*, Haibe-Kains B*, Desmedt C, Lallemand F, Tutt AM, Gillet C, Harris A, Bergh J, Foekens JA, Klijn J, Larsimont D, Buyse M Bontempi G, Delorenszi M, Piccart MJ and Sotiriou C in Journal of Clinical Oncology, volume 25, number 10, April 2007. [Abstract] [PDF] [BibTeX]
    • Reply: Expression profiling in breast carcinoma: new insights on old prognostic factors? Loi S, Haibe-Kains B, Desmedt C, and Sotiriou C in Journal of Clinical Oncology, volume 25, number 27, pages 4317-4318, September 2007. [Abstract] [PDF] [BibTeX]
  • Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis, Sotiriou C, Wirapati P, Loi S, Harris A, Bergh J, Smeds J, Farmer P, Praz V, Haibe-Kains B, Lallemand F, Buyse M, Piccart MJ and Delorenzi M in Journal of National Cancer Institute, volume 98, pages 262-272, February 2006. [Abstract] [PDF] [BibTeX]
  • Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes, Lacroix M, Haibe-Kains B, Hennuy B, Laes JF, Lallemand F, Gonze I, Cardoso F, Piccart MJ, Leclercq G and Sotiriou C in Oncology Reports, volume 12, number 4, pages 701-708, October 2004. [Abstract] [PDF] [BibTeX]
International Conference
  • Correlation of PIK3CA mutation-associated gene expression signature (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers. Loi S, Haibe-Kains B, Lallemand F, Pusztai L, Bardelli A, Gillett C, Ellis P, Piccart-Gebhart MJ, Phillips WA, McArthur GA and Sotiriou C in American Society of Clinical Oncology Meeting, Orlando 2009, poster presentation, 2009. [Abstract] [PDF] [BibTeX]
  • MicroRNA-29c and 223 Are Powerful Prognostic Factors for Chronic Lymphocytic Leukemia and Improve Risk Stratification When Combined with ZAP70 and LPL in a qPCR Score. Stamatopoulos B, Meuleman N, Bron D, Haibe-Kains B, Saussoy P, Martiat P and Lagneaux L in the 50th American Society of Hematology (ASH) Meeting, San Francisco, USA, December 2008. [Abstract] [PDF]
  • Correlation of gene expression analysis of tumor-infiltrating CD4+ cells with immune function and survival according to different breast cancer (BC) molecular subtypes. Sotiriou C, Equeter C, El Ouriaghli F, Haibe-Kains B, Durbecq V, Larsimont D, Igniatiadis M, Desmedt C, Willard-Gallo K and Piccart MJ in the American Society of Clinical Oncology Meeting, abstract #11022. [Abstract] [PDF]
  • Farnesoid X receptor (FXR) status complements the evaluation of estrogen receptor alpha (ER) in breast cancer (BC) patients and predicts benefit from tamoxifen. Journe F, Durbecq V, Haibe-Kains B, Chaboteaux C, Rouas G, Laurent G, Larsimont D, Piccart MJ, Body JJ, Sotiriou C in the European Journal of Cancer Supplements, volume 6, number 7, page 112, April 2008. [Abstract] [PDF] [BibTeX]
  • Molecular qRT-PCR grade index: a new tool for breast cancer (BC) patient grading improvement. Toussaint J, Sieuwerts A, Durbecq V, Haibe-Kains B, Berns E, Harris AL, Larsimont D, Piccart MJ, Foekens J, Sotiriou C in the European Journal of Cancer Supplements, volume 6, number 7, page 140, April 2008. [Abstract] [PDF] [BibTeX]
  • Farnesoid X receptor (FXR): A new marker for the prediction of bone metastases in breast cancer. Journe F, Durbecq V, Chaboteaux C, Rouas G, Haibe-Kains B, IdBoufker H, Laurent G, Sotiriou C, Larsimont D and Body J in the Cancer Treatment Reviews, 2008. [Abstract] [PDF] [BibTeX]
  • CLL patient comparison according to Zap70 mRNA level: new prognostic factors, differences in microRNA expression and distinct interaction capacities with the microenvironment. Stamatopoulos B, Haibe-Kains B, Meuleman N, Bron D, Martiat P and Lagneaux L In the Proceedings of the 13th Congress of the  European Hematology Association (EHA), Copenhagen, Denmark, 2008. [Abstract] [PDF]
  • The nucleolus, a potential target of cardenolide-mediated anti-tumor activity. Mijatovic T, De Neve N, Gailly P, Mathieu V, Haibe-Kains B, Bontempi G, Decaestecker C, Facchini V, Kiss R. In the Proceedings of the Belgium society for cell and developmental biology autumn meeting, Louvain-la-neuve, 2007, abstract #46. [Abstract]
  • ORP150, a major target of Galectin-1 pro-angiogenic effects in human Hs683 glioblastoma xenografts. Lefranc F, Le Mercier M, Mathieu V, Haibe-Kains B, Bontempi G, Mijatovic T, Decaestecker C, Kiss R. In the Proceedings of the Belgium society for cell and developmental biology autumn meeting, Louvain-la-neuve, 2007, abstract #31. [Abstract] [PDF]
  • Galectin-1 regulates P53 and is implicated in glioma cell resistance to cytotoxic drugs. Le Mercier M, Lefranc F, Mijatovic T, Debeir O, Haibe-Kains B, Bontempi G, Decaestecker C, Kiss R, Mathieu V. In the Proceedings of the Belgium society for cell and developmental biology autumn meeting, Louvain-la-neuve, 2007, abstract #33. [Abstract] [PDF]
  • Interactions between breast cancer cells and their stromal component: an analysis of alterations in gene expressionSotiriou C, El Ouriaghli F, Majjaj S, Haibe-Kains B, Desmedt C, Lallemand F, Larsimont D, Piccart MJ in San Antonio Breast Cancer Symposium 2007, poster #3092, San Antonio, Texas, USA[Abstract] [PDF]
  • Meta-analysis of gene-expression profiles in breast cancer: towards a unified understanding of breast cancer sub-typing and prognosis signatures. Sotiriou C, Wirapati P, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Sengstag T, Schütz F, Goldstein DR, Delorenzi M, Piccart MJ in Breast Cancer Research and Treatment, volume 106, supplement 1, pages S56-S7, 2007[Abstract] [PDF]
  • Gene expression profiling identifies potential therapeutic targets in estrogen receptor positive breast cancer. Loi SHaibe-Kains B, Sotiriou C, Lallemand F, Piccart MJ, Campbell I, Wayne P and McArthur GA in the American Society of Clinical Oncology Meeting, San Francisco 2007, poster, 2007. [Abstract] [PDF]
  • Gene expression comparison between B cells expressing high and low level of Zap-70 mRNA reveals distinct profiles, potential therapeutic targets and new prognostic factors for Chronic Lymphocytic Leukemia. Stamatopoulos B, Equeter C, Haibe-Kains B, Soree A, Sotiriou C, Bron D, Martiat P, Lagneaux L in the 12th Congress of the European Hematology Association, Neue Messe Vienna, Austria, June 7 - 10, 2007, abstract #0513. [Abstract] [PDF]
  • Zap-70 mRNA expression quantified in B cell by real time PCR is a powerful prognostic factor in Chronic Lymphocytic Leukemia. Stamatopoulos B, Meuleman N, Haibe-Kains B, Duvillier H, Massy M, Martiat P, Bron D, Lagneaux L in the 12th Congress of the European Hematology Association, abstract #0111, Neue Messe Vienna, Austria, June 7 - 10, 2007[Abstract] [PDF]
  • Identification of potential therapeutic targets in estrogen receptor-positive breast cancer by gene expression profilingLoi S, Haibe-Kains B, Phillips WA, Lallemand F, Campbell IG, Piccart MJ, Sotiriou C and McArthur GA in the American Society of Clinical Oncology Meeting, abstract #26, Chicago, 2007. [Abstract]
  • Investigating tamoxifen resistance in the luminal B estrogen receptor positive breast cancer subtype: Tailoring treatment in hormone responsive breast cancer. Loi S, Sotiriou C, Haibe-Kains B, Lallemand F, Conus N, Piccart MJ, Speed T and McArthur GA. in the Proceedings of the American Society of Clinical Oncology Meeting, abstract #10603, Chicago 2007[Abstract] [PDF]
  • Biological mechanisms that trigger breast cancer (BC) tumor progresion are molecular subtype dependent. Sotiriou C, Desmedt C, Haibe-Kains B, Harris A, Larsimont D, Buyse M, Wirapati P, Delorenzi M, Bontempi G and Piccart MJ in the Proceedings of the American Society of Clinical Oncology Meeting, abstract #10581, Chicago 2007[Abstract] [PDF]
  • Gene expression profiling can predict pathological complete response (pCR) to anthracycline-based therapy in estrogen-receptor (ER) negative breast cancer (BC) patients.  Desmedt C, Andre F, Azambuja E, Haibe-Kains B, Larsimont D, D’Hondt V, Di Leo A, Piccart MJ, Pusztai L and Sotiriou C in the Proceedings of the American Society of Clinical Oncology Meeting, Chicago 2007, abstract #10564. [Abstract] [PDF]
  • Transforming genomic grade index (GGI) into a user-friendly qRT-PCR tool which will assist clinicians and patients in optimizing treatment of early breast cancer (BC)Durbecq V, Toussaint J, Haibe-Kains B, Desmedt C, Rouas G, Larsimont D, Buyse M, Bontempi G, Piccart MJ and Sotiriou C in the Proceedings of the American Society of Clinical Oncology Meeting, Chicago 2007, abstract #21058. [Abstract]
  • CD4+ T cells infiltrating breast tumors exhibit altered expression of T cell immune response genes in comparison with their counterparts from the lymph node and blood. Equeter C, El Ouriaghli F, Haibe-Kains B, Stamatopoulos B, André F, Lallemand F, Filippov V, Larsimont D, Sotiriou C and Willard-Gallo K. in the Fourth International Conference on Tumor Microenvironment (AACR), Florence,  2006. [Abstract] [PDF]
  • Comprehensive molecular analysis of several prognostic signatures using molecular indices related to hallmarks of breast cancer: proliferation index appears to be the most significant component of all signatures. Sotiriou C, Haibe-Kains B, Desmedt C, Wirapati P, Durbecq V, Harris A, Larsimont D, Bontempi G, Buyse M, Delorenzi M and Piccart MJ. in the San Antonio Breast Cancer Symposium 2006, poster #2020 published in Breast Cancer Research and Treatment, supplement 1, volume 100, page S86, 2006. [Abstract] [PDF]
  • Gene expression profiling can predict pathological complete response (pCR) to anthracycline-monotherapy in estrogen-receptor (ER) negative breast cancer (BC) patients. Desmedt C, Azambuja E, Di Leo A, Larsimont D, Durbecq V, Antoine D, Lallemand F, Haibe-Kains B, Cardoso F, Nogaret JM, Fontaine D, Liebens F, Duhem C, Kains JP, Maerevoet M, Richard V, Vindevoghel A, Delaloge S, Buyse M, D’Hondt V, Piccart MJ and Sotiriou C. in the San Antonio Breast Cancer Symposium 2006, poster #3022 published in Breast Cancer Research and Treatment, supplement 1, volume 100, page S131, 2006[Abstract] [PDF]
  • Decreasing Galectin-1 Expression in Human Hs683 Glioblastoma Cells Impairs their Response to Endoplasmic Reticulum Stress. Le Mercier M, Camby I, Mathieu V, Dumont P, De Neve N, Roland I, Haibe-Kains B, Bontempi G, Mijatovic T, Kondo Y, Decaestecker C, Kiss R and Lefranc F. In the Proceedings of the Belgium society for cell and developmental biology autumn meeting, Gent, 2006, abstract #23. [Abstract] [PDF]
  • Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1500 samples: Proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer (BC). Sotiriou C, Wirapati P, Loi S, Haibe-Kains B, Desmedt C, Tutt A., Ellis P., Buyse M, Delorenzi M and Piccart MJ in the American Society of Clinical Oncology, oral presentation, abstract #507, Atlanta 2006[Abstract] [PDF] [BibTeX]
  • TRANSBIG multi-centre independent validation of the Rotterdam 76-gene prognostic signature for patients with node-negative breast cancer. Desmedt C,  Piette F, Cardoso F, Y. Wang, Loi S, Lallemand F, Klijn J, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, Saghatchian d'Assignies M, Bergh J, Lidereau R, Ellis P, Harris A, Foekens J, Buyse M, Piccart MJ and Sotiriou C in the European Breast Cancer Conference 2006, presidential session[Abstract] [PDF]
  • Is genomic grading killing histological grading ? Sotiriou C, Wirapati P, Loi S, Desmedt C, Haibe-Kains B, Piette F, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, in the European Breast Cancer Conference 2006, presidential session, published in European Journal of Cancer Supplements, volume 4, number 2, page 177[Abstract] [PDF]
  • Better characterization of estrogen receptor (ER) positive luminal subtypes using genomic grade. Sotiriou C, Wirapati P, Loi S, Desmedt C, Durbecq V, Harris A, Bergh J, Smeds J, Haibe-Kains B, Larsimont D, Cardoso F, Buyse M, Delorenzi M and Piccart MJ in the San Antonio Breast Cancer Symposium 2005, general session #37 published in Breast Cancer Research and Treatment, volume 94, supplement 1, page S19, 2005. [Abstract] [PDF]
  • Four genes by RT-PCR predicts distant relapse for women given adjuvant tamoxifen. Desmedt C, Loi S, Haibe-Kains B, Soree A, Lallemand F, Durbecq V, Larsimont D, Tutt A, Ellis P, Gillett C, Ryder K, Harris A, Cardoso F, Martiat PH, Piccart MJ and Sotiriou C in the  San Antonio Breast Cancer Symposium 2005, poster session #3025 published in Breast Cancer Research and Treatment, volume 94, supplement 1, page S133, 2005. [Abstract] [PDF]
  • Predicting relapse in estrogen receptor (ER) positive breast cancer (luminal) subgroups treated with adjuvant tamoxifen. Loi S, Desmedt C, Haibe-Kains B, Lallemand F, Gillett C, Tutt A, Ryder K, Ellis P, Harris A, Smeds J, Bergh J, Cardoso F, Piccart MJ, Sotiriou C. in the  San Antonio Breast Cancer Symposium 2005, poster session #3016 published in Breast Cancer Research and Treatment, volume 94, supplement 1, page S129, 2005[Abstract] [PDF] 
  • Breast tumours with intermediate histological grade can be reclassified into prognostically distinct groups by gene expression profiling. Sotiriou C, Wirapati P, Loi S, Viale G, Harris A, Bergh J, Smeds J, Farmer P, Praz V, Haibe-Kains B, Lallemand F, Desmedt C, Durbecq V, Larsimont D, Cardoso F, Buyse M, Delorenzi M and Piccart MJ in the San Antonio Breast Cancer Symposium 2005, poster discussion #302 published in Breast Cancer Research and Treatment, volume 94, supplement 1, page S30, 2005.  [Abstract] [PDF]
  • Prediction of early distant relapses on tamoxifen in early-stage breast cancer (BC): a potential tool for adjuvant aromatase inhibitor (AI) tailoring. Loi S, Piccart MJ, Haibe-Kains B, Desmedt C, Harris A, Bergh J, Ellis P, Miller L, Liu E and Sotiriou C in the Proceedings of the American Society of Clinical Oncology Meeting, Orlando 2005, abstract #509. [Abstract] [PDF] [BibTeX]
  • Gene expression profiling in breast cancer challenges the existence of intermediate histological grade. Sotiriou C, Wirapati P, Loi S, Harris A, Bergh J, Smeds J, Praz V, Farmer P, Haibe-Kains B, Lallemand F, Buyse M, Piccart MJ and Delorenzi M presented at the Fifth International Meeting on Statistical Methods in Biopharmacy, Paris, France, September 26-27, 2005. [Abstract]
  • Gene expression profiling in breast cancer challenges the existence of the intermediate histological grade. Sotiriou C, Wirapati P, Loi S, Harris A, Bergh J, Smeds J, Farmer P, Praz V, Haibe-Kains B, Lallemand F, Buyse M, Piccart MJ and Delorenzi M in the Third International Symposium on the Molecular Biology of Breast Cancer Molde, Norway. Published in Breast Cancer Research, volume 7, supplement 2, page 4.33, 2005. [Abstract] [PDF]
  • Potential importance of PKC-alpha activity in defining breast tumor luminal/basal phenotype. Lacroix M, Haibe-Kains B, Laes JF, Hennuy B, Cardoso F, Lallemand F, Gonze I, Leclercq G, Piccart MJ and Sotiriou C in the San Antonio Breast Cancer Symposium 2003, poster session #671. [Abstract] [PDF]
National Conference
  • Microrna-29c and microrna-223 downregulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van Den Neste E, Michaux L, Heimann P, Martiat P, Bron D, Lagneaux L in the Belgian Hematology Society (BHS) Annual General Meeting 2009, 30th of January 2008, Oostende, Belgium. [Abstract]
  • Identification of Breast Cancer Molecular SubtypesHaibe-Kains B in the Televie 2007 seminar, 26th November 2008, Liege, Belgium. [Abstract] [PDF] [BibTex]
  • Comparison of chronic lymphocytic leukemia patients expressing high or low level of ZAP70 mRNA: new prognostic factors differences in microRNA expression and interaction with the microenvironment. Stamatopoulos B, Haibe-Kains B, Equeter C, Debruyn C, Meuleman M, Hanosset D, Sorree A, Bron D, Martiat M, Lagneaux L in the Belgian Hematology Society (BHS) Annual General Meeting 2008
    25th of January 2008, Oostende, Belgium. 
    [Abstract] [PPT]
  • Comparison of Prognostic Gene Expression signatures for Breast CancerHaibe-Kains B, C. Desmedt, G. Bontempi and Sotiriou C in the Televie 2007 seminar, 5th December 2007, Brussels, Belgium. [Abstract] [PDF]
  • Comprehensive analysis integrating both clinico-pathological and gene expression data in more than 1500 samples: Proliferation captured by gene expression grade index appears to be thestrongest prognostic factor in breast cancerene Expression Analaysis of Tamoxifen Resistance in Breast CancerDesmedt C, Haibe-Kains B, and Sotiriou C in the Televie 2006 seminar, 6th of December 2006, Brussels, Belgium. [PDF]
  • Gene Expression Analaysis of Tamoxifen Resistance in Breast CancerHaibe-Kains B, Loi S, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Harris A, Bergh J, Larsimont D, Buyse M, Bontempi G, Piccart MJ and Sotiriou C in Computational Learning and Intelligence, research Contact Day, 25th of September 2006, Brussels, Belgium. [PDF]
Workshops
  • Class Discovery and Class Prediction from Human Cancer Microarray Datasets. Haibe-Kains B, Sotiriou C and Bontempi G in OECI course program about Microarray Data Generation and Analysis, 28th February 2006, Brussels, Belgium. [PDF]
Invited Talks
  • Introduction to MiroArrays and Gene-Expression Profiling and Statistical analyis of MicroArray Data. Haibe-Kains B, Sotiriou C and Bontempi G in IDDI (International Drug Development Institute) meeting, 23th of March 2007, Louvain-La-Neuve, Belgium. [PDF] [PDF]
  • Gene Expression Analysis : Tamoxifen Resistance in Breast CancerHaibe-Kains B, Loi S, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Harris A, Bergh J, Larsimont D, Buyse M, Bontempi G, Piccart MJ and Sotiriou C in CINBIOS (centre de BioInformatique et BioModelisation) meeting, 29th of September 2006, Brussels, Belgium. [PDF]
Thesis
  • Identification and Assesment of Gene Signatures in Human Breast Cancer [PDF] [BibTeX]
PhD Thesis in Bioinformatics at the Universite Libre de Bruxelles under the supervision of Prof. Gianluca Bontempi and Prof. Christos Sotiriou, Belgium, April 2009.
  • Use of Machine Learning in Bioinformatics to Identify Prognosis and Predictive Molecular Signatures in Human Breast Cancer [PDF] [BibTeX]
Master Thesis in Sciences at the Universite Libre de Bruxelles under the supervision of Prof. Gianluca Bontempi and Prof. Christos Sotiriou, Belgium, June 2005.
The summary and the presentation are given here
Master Thesis in Bioinformatics at the Universite Libre de Bruxelles under the supervision of Prof. Gianluca Bontempi and Prof. Christos Sotiriou, Belgium, July 2004. 
The summary and the presentation are given here
  • Apprentissage d'une tache de controle pour un robot mobile en LEGO Mindstorms [PDF] [BibTeX]
Thesis in Computer Science at the Universite Libre de Bruxelles under the supervision of Prof. Gianluca Bontempi, Belgium, September 2003. 
The summary and the presentation are given here